Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$808.21 USD

808.21
907,273

-10.72 (-1.31%)

Updated Nov 4, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Company News For Jan 8, 2019

Companies In The News Are: LOXO,LLY,DLTR,PCG,MAT

Ekta Bagri headshot

4 Biotechs That Are Potential Buyouts Post Celgene Deal

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.

Eli Lilly (LLY) Gains But Lags Market: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $115.28, moving +0.54% from the previous trading session.

Biogen Inks Two Deals to Make Drugs for Neurological Diseases

Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.

Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate

Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.

Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration

Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.

The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily

The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily

Swarup Gupta headshot

5 Great S&P 500 Stocks to Buy in 2019

A near-term recession seems unlikely, the job market remains robust and the trade dispute with China could be resolved this year.

Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

Is (LLY) Outperforming Other Medical Stocks This Year?

Teva Stock Rises on Patent Settlement With Neos Therapeutics

Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.

Kinjel Shah headshot

Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019

J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.

Bayer (BAYRY) Faces Generic Threat & Rising Competition

Bayer (BAYRY) is facing generic threats/competition for many of its products. The genericization of key drugs will negatively impact revenues.

Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study

Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.

Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations

Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.

Lilly's Shares Rise on Robust 2019 View, Dividend Hike

Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.

Allergan Drops, Stops Textured Breast Implant Sales in Europe

Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.

The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab

The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab

Company News For Dec 20, 2018

Companies In The News Are: FDX,GIS,LLY,PFE,GSK

Aduro Stock Surges on STING Activator Deal With Eli Lilly

Aduro (ADRO) inks a collaboration/license deal with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.

Mark Vickery headshot

Top Analyst Reports for Eli Lilly, Mitsubishi UFJ & Thermo Fisher

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Mitsubishi UFJ Financial Group, Inc. (MUFG) and Thermo Fisher Scientific Inc. (TMO).

Lilly's Taltz Outshines Humira in Psoriatic Arthritis Study

Eli Lilly's (LLY) Taltz displays superiority over standard of care medicine Humira in a head-to-head study on patients with active psoriatic arthritis.

Teva Reports Positive Top-Line Data for Migraine Candidate

Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.

Merck to Acquire Europe's Antelliq Group for $2.4 Billion

Merck (MRK) secures an acquisition deal to purchase French animal health company Antelliq Group for a consideration of around $2.4 billion.

Incyte (INCY) Collaborates with Innovent for 3 Candidates

Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.

Lilly (LLY) to Acquire Pain Candidate From Private Biotech

Lilly (LLY) inks a deal with privately held Hydra Biosciences to add the latter's pre-clinical pain candidate to its portfolio.